Radiation Toxicity Treatment Market Size, Share | Industry Report 2024

The global radiation syndrome treatment market is worth $ 4,655 Million in 2016 and expected to be $ 8,256 Million by 2024 growing at a CAGR of 6.57%.

Industry at a Glance

Rising tension and missile warfare at Korean peninsula putting world at crossroad of possible dangerous nuclear disaster. A 10-kiloton detonation to city population like Virginia (with a population of 2 million) can bring more than 270,000 Acute Radiation Syndrome incidents. Hence major federal governments of the world are keeping them prepared for the treatment.

Some of the leading players in the market have been assessed using three major parameters such as Product portfolio, Government funding and Market Dominance. In addition, few other parameters considered include financials, technological advancements and product reviews from end users. Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services. Their range of products developed has application from Acute Radiation Syndrome to Nerve gas exposure.

U.S being the largest market because of its sensitive military activities and threat perception. It accounted for xx % of the market share in 2016 ($ x,xxx Million) and will keep growing to occupy 54% of the global market. Middle East market in decline trend due to moving out of U.S troops and reducing threat perception. In Europe, UK, Germany, France represent significant market

In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.

Click the link below to view the report description:
www.ameriresearch.com/product/radiation-toxicity-treatment-market-size/

Key findings from the study: -
• Among the companies evaluated, Aeolus Pharmaceutical promised to be a significant player. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (“Lung-ARS”) under a $118MM, 5-year contract from the Biomedical Advanced Research and Development Authority (“BARDA”), a division of the U.S. Department of Health and Human Services.
• In Asia, Japan and Korea are the markets with huge demand for the Acute Radiation Syndrome treatment modalities. Aeolus also has collaboration with Israel, Japan, and South Korea governments to supply their biodefense products. Their product AEOL-10150 has emergency use authorization prior FDA approval. Onconova Therapeutics’ Recilisib is a product candidate being developed in collaboration with the U.S. Department of Defense for acute radiation syndromes.
• key market players include Agilent Technologies, Waters Corporation, Phenomenex Inc., Sartorius AG, Daicel Corporation, Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation, Shimadzu Corporation, GE Healthcare, W.R. Grace, and Regis Technologies.

Ameri Research has segmented the Radiation Toxicity Treatment Market by Type of Exposure, Radiation Type, Disease Type and Regional Outlook.
Market Segmentation

Radiation Toxicity Treatment Market by “Type of Exposure” (Revenue, USD Million, 2014- 2024)
• Acute radiation syndrome (ARS) (Single large exposure)
• Chronic Radiation Syndrome (Small exposures spread over time)

Radiation Toxicity Treatment Market by “Radiation Type” (Revenue, USD Million, 2014- 2024)
• Ionizing (Alpha/Beta/Gama)
• Non-Ionizing

Radiation Toxicity Treatment Market by “Disease Type” (USD Million) (Revenue, USD Million, 2014- 2024)
• Bone Marrow Syndrome (Hematopoietic)
• Gastrointestinal Syndrome (GI)
• Cardiovascular (CV)
• Central Nervous System (CNS) Syndrome

Radiation Toxicity Treatment Market Regional Outlook (Revenue, USD Million, 2014- 2024)
• North America
o U.S.
o Canada

• Europe
o UK
o Germany
o France
o Italy
o Spain

• Asia Pacific
o Japan
o China
o India
o Australia

• Latin America
o Brazil
o Mexico
o Columbia

• Middle East and Africa
o South Africa
o Saudi Arabia

Browse Full Report @ www.ameriresearch.com/product/radiation-toxicity-treatment-market-size/

About Us:

Ameri Research Inc. (www.ameriresearch.com) is a U.S. based market research and consulting company, registered in the State of Florida and headquartered in Tampa Bay Area. At Ameri Research we are passionately curious about people, markets, brands and society. Our ability to gauge market movements, deep expertise in data science, strong domain expertise and years of collective global experiences helps us to bring unmatched quality in deliverables to our clients. With carefully planned systems and processes in place, we cater to the requirements of our clients in a timely and cost-efficient manner, bringing increased predictability to their business. Each year we are publishing more than 100 syndicated reports in healthcare, chemicals, materials, food & beverages, defense & aerospace, media & entertainment, sports & fitness, and energy. We offer our clients a unique depth of knowledge and expertise around-

Market Mapping
Opportunity Assessment
Positioning
Pricing Analysis
Market Entry Strategy
Competitive Intelligence
Program Evaluation
Performance Reporting
Data Analytics
Developing a culture of collaboration and curiosity, we attract the highest caliber of likeminded people having ability to influence and shape the future.

Follow us on LinkedIn for our latest upcoming reports www.linkedin.com/company/ameri-research-inc./
Follow us on Facebook for our latest upcoming reports www.facebook.com/AmeriResearchInc/
Follow us on Twitter for our latest upcoming reports www.twitter.com/AmeriResearch

Contact Us:

Ameri Research Inc.
6816 Muncaster Ct,
Tampa, FL 33625
United States.
Tel: 1-813-666-0858
Email: Inquiry@ameriresearch.com
Web: www.ameriresearch.com

This release was published on openPR.